Electrochemotherapy for rectal cancer after neoadjuvant radiotherapy: A case report

Scala, D.; Rega, Daniela; Ruffolo, F.; Pace, Ugo; Sassaroli, C.; Cardone, E.; Grimaldi, Antonio; Caracò, Corrado; Mozzillo, Nicola; Delrio, Paolo

doi:10.1016/j.ejso.2014.10.037

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The International Network on Sharing Practices on Electrochemotherapy (InspECT) reported an overall response rate in 74% of 114 patients with metastatic malignant melanoma and 78% of 394 lesions treated by ECT using intravenous or intratumoral injection of bleomycin [ 70 ]. Today, a wider range of subjects are eligible for treatment, and research into use in colorectal cancer [ 71 ], hepatocellular carcinoma [ 14 ], and liver metastases [ 13 , 72 ] is ongoing.…”

Section: Current Clinical Application Of Ectmentioning

confidence: 99%

Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions

Enokida¹,

Tahara²

2021

Cancers

View full text Add to dashboard Cite

Despite recent advances in the development of chemotherapeutic drug, treatment for advanced cancer of the head and neck cancer (HNC) is still challenging. Options are limited by multiple factors, such as a prior history of irradiation to the tumor site as well as functional limitations. Against this background, electrochemotherapy (ECT) is a new modality which combines administration of an antineoplastic agent with locally applied electric pulses. These pulses allow the chemotherapeutic drug to penetrate the intracellular space of the tumor cells and thereby increase its cytotoxicity. ECT has shown encouraging efficacy and a tolerable safety profile in many clinical studies, including in heavily pre-treated HNC patients, and is considered a promising strategy. Efforts to improve its efficacy and broaden its application are now ongoing. Moreover, the combination of ECT with recently developed novel therapies, including immunotherapy, represented by immune checkpoint inhibitor (ICI)s, has attracted attention for its potent theoretical rationale. More extensive, well-organized clinical studies and timely updating of consensus guidelines will bring this hopeful treatment to HNC patients under challenging situations.

show abstract

Section: Current Clinical Application Of Ectmentioning

confidence: 99%

Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions

Enokida¹,

Tahara²

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Since then, electrochemotherapy has undergone numerous trials on advanced malignant melanoma, and non-melanoma skin cancer [11,12,[15][16][17][18], recurrent breast cancer [19] and Kaposi's sarcoma [20]. Today, electrochemotherapy is mainly used for cutaneous treatment of primary or recurrent tumors and metastases [21]; however, research is ongoing for the use of electrochemotherapy in the treatment of colorectal cancer [22] and liver metastases [23]. Furthermore, novel drug agents are being explored such as calcium [24] and mitomycin C [25].…”

Section: Electrochemotherapymentioning

confidence: 99%

Electrochemotherapy of mucosal head and neck tumors: a systematic review

et al. 2016

View full text Add to dashboard Cite

show abstract

“…It is also of great interest for people diagnosed with cutaneous malignancies at advanced ages as it offers an efficient, safe nonsurgical treatment [14]. Research is still ongoing for treatment of deep-seated tumors such as colorectal cancer [15] and liver metastases [16]. Other modalities, such as calcium electroporation, where cytotoxic drugs are replaced by high concentration level of calcium, also showed great promise [17].…”

Section: Introductionmentioning

confidence: 99%

Single Cell Microwave Biosensor for Monitoring Cellular Response to Electrochemotherapy

Tamra

Zedek

Rols

et al. 2022

IEEE Trans. Biomed. Eng.

View full text Add to dashboard Cite

This paper presents a 40 GHz microwave biosensor used to monitor and characterize single cells (THP-1) subjected to electrochemotherapy and obtain an electronic signature of the treatment efficiency. This biosensor proposes a non-destructive and label-free technique that first allows, with the rapid measurement of single untreated cells in their culture medium, the extraction of two frequency-dependent dielectric parameters, the capacitance (C (f)) and the conductance (G (f)). Second, this technique can powerfully reveal the effects of a chemical membrane permeabilizing treatment (Saponin). At last, it permits us to detect, and predict, the potentiation of a molecule classically used in chemotherapy (Bleomycin) when combined with the application of electric pulses (principle of electrochemotherapy). Treatment-affected cells show a decrease in the capacitive and conductive contrasts, indicating damages at the cellular levels. Along with these results, classical biological tests are conducted. Statistical analysis points out a high correlation rate (R 2 >0.97), which clearly reveals the reliability and efficacy of our technique and makes it an attractive technique for biology related researches and personalized medicine.

show abstract

Electrochemotherapy for rectal cancer after neoadjuvant radiotherapy: A case report

Cited by 5 publications

References 0 publications

Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions

Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions

Electrochemotherapy of mucosal head and neck tumors: a systematic review

Single Cell Microwave Biosensor for Monitoring Cellular Response to Electrochemotherapy

Contact Info

Product

Resources

About